In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:

Biocontrol Technology

This article was originally published in The Gray Sheet

  • News

Executive Summary

BICO, Inc. subsidiary CEO and President David Purdy resigns following disagreement with parent company Chairman Fred Cooper over funding levels related to development of the Diasensor 2000 noninvasive blood glucose monitor, for which clinical trials are ongoing. Purdy, who resigned as BICO chairman in May to focus on the Diasensor, also faults a Sept. 8 BICO letter to stockholders for inaccuracies relating to the device. BICO maintains that "to date in year 2000, [it] has funded the Diasensor project in excess of $14 mil., which exceeds budget requirements by over $1 mil"
Table

View full table

Advertisement
Advertisement
Advertisement
Tags:
UsernamePublicRestriction

Register

MT014122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By